• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form SCHEDULE 13G/A filed by Anika Therapeutics Inc.

    11/7/25 6:06:11 AM ET
    $ANIK
    Medical/Dental Instruments
    Health Care
    Get the next $ANIK alert in real time by email



    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549


    SCHEDULE 13G


    UNDER THE SECURITIES EXCHANGE ACT OF 1934
    (Amendment No. 3)


    Anika Therapeutics, Inc.

    (Name of Issuer)


    Common Stock, Par Value $0.01 Per Share

    (Title of Class of Securities)


    035255108

    (CUSIP Number)


    09/30/2025

    (Date of Event Which Requires Filing of this Statement)


    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
    Checkbox checked   Rule 13d-1(b)
    Checkbox not checked   Rule 13d-1(c)
    Checkbox not checked   Rule 13d-1(d)






    SCHEDULE 13G

    CUSIP No.
    035255108


    1Names of Reporting Persons

    Trigran Investments, Inc.
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    ILLINOIS
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    1,532,791.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    1,621,215.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    1,621,215.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    11.2 %
    12Type of Reporting Person (See Instructions)

    IA, CO

    Comment for Type of Reporting Person:  The Reporting Person disclaims beneficial ownership of the shares reported in this Schedule 13G, except to the extent of its pecuniary interest.


    SCHEDULE 13G

    CUSIP No.
    035255108


    1Names of Reporting Persons

    Douglas T. Granat
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    UNITED STATES
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    1,532,791.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    1,621,215.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    1,621,215.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    11.2 %
    12Type of Reporting Person (See Instructions)

    HC, IN

    Comment for Type of Reporting Person:  The Reporting Person disclaims beneficial ownership of the shares reported in this Schedule 13G, except to the extent of its pecuniary interest.


    SCHEDULE 13G

    CUSIP No.
    035255108


    1Names of Reporting Persons

    Lawrence A. Oberman
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    UNITED STATES
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    1,532,791.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    1,621,215.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    1,621,215.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    11.2 %
    12Type of Reporting Person (See Instructions)

    HC, IN

    Comment for Type of Reporting Person:  The Reporting Person disclaims beneficial ownership of the shares reported in this Schedule 13G, except to the extent of its pecuniary interest.


    SCHEDULE 13G

    CUSIP No.
    035255108


    1Names of Reporting Persons

    Steven G. Simon
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    UNITED STATES
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    1,532,791.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    1,621,215.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    1,621,215.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    11.2 %
    12Type of Reporting Person (See Instructions)

    HC, IN

    Comment for Type of Reporting Person:  The Reporting Person disclaims beneficial ownership of the shares reported in this Schedule 13G, except to the extent of its pecuniary interest.


    SCHEDULE 13G

    CUSIP No.
    035255108


    1Names of Reporting Persons

    Bradley F. Simon
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    UNITED STATES
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    1,532,791.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    1,621,215.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    1,621,215.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    11.2 %
    12Type of Reporting Person (See Instructions)

    HC, IN

    Comment for Type of Reporting Person:  The Reporting Person disclaims beneficial ownership of the shares reported in this Schedule 13G, except to the extent of its pecuniary interest.


    SCHEDULE 13G

    CUSIP No.
    035255108


    1Names of Reporting Persons

    Steven R. Monieson
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    UNITED STATES
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    1,532,791.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    1,621,215.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    1,621,215.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    11.2 %
    12Type of Reporting Person (See Instructions)

    HC, IN

    Comment for Type of Reporting Person:  The Reporting Person disclaims beneficial ownership of the shares reported in this Schedule 13G, except to the extent of its pecuniary interest.


    SCHEDULE 13G

    Item 1. 
    (a)Name of issuer:

    Anika Therapeutics, Inc.
    (b)Address of issuer's principal executive offices:

    32 Wiggins Avenue Bedford, MA, 01730
    Item 2. 
    (a)Name of person filing:

    See Item 2(c)
    (b)Address or principal business office or, if none, residence:

    See Item 2(c)
    (c)Citizenship:

    Trigran Investments, Inc., 630 Dundee Road, Suite 230, Northbrook, IL 60062 (Illinois corporation) Douglas T. Granat, 630 Dundee Road, Suite 230, Northbrook, IL 60062 (U.S. Citizen) Lawrence A. Oberman, 630 Dundee Road, Suite 230, Northbrook, IL 60062 (U.S. Citizen) Steven G. Simon, 630 Dundee Road, Suite 230, Northbrook, IL 60062 (U.S. Citizen) Bradley F. Simon, 630 Dundee Road, Suite 230, Northbrook, IL 60062 (U.S. Citizen) Steven R. Monieson, 630 Dundee Road, Suite 230, Northbrook, IL 60062 (U.S. Citizen)
    (d)Title of class of securities:

    Common Stock, Par Value $0.01 Per Share
    (e)CUSIP No.:

    035255108
    Item 3.If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
    (a)Checkbox not checked   Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
    (b)Checkbox not checked   Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
    (c)Checkbox not checked   Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
    (d)Checkbox not checked   Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
    (e)Checkbox checked   An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
    (f)Checkbox not checked   An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
    (g)Checkbox checked   A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
    (h)Checkbox not checked   A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
    (i)Checkbox not checked   A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
    (j)Checkbox not checked   A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
           please specify the type of institution:
    (k)Checkbox not checked   Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
     
    Item 4.Ownership
    (a)Amount beneficially owned:

    Incorporated by reference to Item 9 of the cover page pertaining to each reporting person. Douglas Granat, Lawrence A. Oberman, Steven G. Simon, Bradley F. Simon, and Steven R. Monieson are the controlling shareholders and officers of Trigran Investments, Inc. and thus may be considered the beneficial owners of shares beneficially owned by Trigran Investments, Inc.
    (b)Percent of class:

    Incorporated by reference to Item 11 of the cover page pertaining to each reporting person.
    (c)Number of shares as to which the person has:
     (i) Sole power to vote or to direct the vote:

    Incorporated by reference to Item 5 of the cover page pertaining to each reporting person.

     (ii) Shared power to vote or to direct the vote:

    Incorporated by reference to Item 6 of the cover page pertaining to each reporting person.

     (iii) Sole power to dispose or to direct the disposition of:

    Incorporated by reference to Item 7 of the cover page pertaining to each reporting person.

     (iv) Shared power to dispose or to direct the disposition of:

    Incorporated by reference to Item 8 of the cover page pertaining to each reporting person.

    Item 5.Ownership of 5 Percent or Less of a Class.
     
    Item 6.Ownership of more than 5 Percent on Behalf of Another Person.
     
    Not Applicable
    Item 7.Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
     
    Not Applicable
    Item 8.Identification and Classification of Members of the Group.
     
    Not Applicable
    Item 9.Notice of Dissolution of Group.
     
    Not Applicable

    Item 10.Certifications:
     
    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

        SIGNATURE 
     
    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     
    Trigran Investments, Inc.
     
    Signature:/s/ Lawrence A. Oberman
    Name/Title:Executive Vice President
    Date:11/07/2025
     
    Douglas T. Granat
     
    Signature:/s/ Douglas T. Granat
    Name/Title:Douglas T. Granat
    Date:11/07/2025
     
    Lawrence A. Oberman
     
    Signature:/s/ Lawrence A. Oberman
    Name/Title:Lawrence A. Oberman
    Date:11/07/2025
     
    Steven G. Simon
     
    Signature:/s/ Steven G. Simon
    Name/Title:Steven G. Simon
    Date:11/07/2025
     
    Bradley F. Simon
     
    Signature:/s/ Bradley F. Simon
    Name/Title:Bradley F. Simon
    Date:11/07/2025
     
    Steven R. Monieson
     
    Signature:/s/ Steven R. Monieson
    Name/Title:Steven R. Monieson
    Date:11/07/2025
    Exhibit Information

    Exhibit 1: Agreement to Make a Joint Filing

    Get the next $ANIK alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ANIK

    DatePrice TargetRatingAnalyst
    4/17/2025$21.00Buy
    B. Riley Securities
    11/1/2024$37.00 → $25.00Outperform
    Barrington Research
    8/14/2023$24.00Mkt Perform → Outperform
    Barrington Research
    3/7/2023Outperform → Mkt Perform
    Barrington Research
    11/9/2022$31.00Mkt Perform → Outperform
    Barrington Research
    10/14/2022$26.00Equal-Weight
    Stephens
    3/9/2022Outperform → Mkt Perform
    Barrington Research
    3/9/2022Overweight → Equal-Weight
    Stephens & Co.
    More analyst ratings

    $ANIK
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    B. Riley Securities initiated coverage on Anika Therapeutics with a new price target

    B. Riley Securities initiated coverage of Anika Therapeutics with a rating of Buy and set a new price target of $21.00

    4/17/25 8:32:06 AM ET
    $ANIK
    Medical/Dental Instruments
    Health Care

    Barrington Research reiterated coverage on Anika Therapeutics with a new price target

    Barrington Research reiterated coverage of Anika Therapeutics with a rating of Outperform and set a new price target of $25.00 from $37.00 previously

    11/1/24 10:25:08 AM ET
    $ANIK
    Medical/Dental Instruments
    Health Care

    Anika Therapeutics upgraded by Barrington Research with a new price target

    Barrington Research upgraded Anika Therapeutics from Mkt Perform to Outperform and set a new price target of $24.00

    8/14/23 9:16:10 AM ET
    $ANIK
    Medical/Dental Instruments
    Health Care

    $ANIK
    SEC Filings

    View All

    Amendment: SEC Form SCHEDULE 13G/A filed by Anika Therapeutics Inc.

    SCHEDULE 13G/A - Anika Therapeutics, Inc. (0000898437) (Subject)

    11/7/25 6:06:11 AM ET
    $ANIK
    Medical/Dental Instruments
    Health Care

    SEC Form S-8 filed by Anika Therapeutics Inc.

    S-8 - Anika Therapeutics, Inc. (0000898437) (Filer)

    11/5/25 4:01:24 PM ET
    $ANIK
    Medical/Dental Instruments
    Health Care

    SEC Form 10-Q filed by Anika Therapeutics Inc.

    10-Q - Anika Therapeutics, Inc. (0000898437) (Filer)

    11/5/25 4:01:00 PM ET
    $ANIK
    Medical/Dental Instruments
    Health Care

    $ANIK
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    $ANIK
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Anika Reports Third Quarter 2025 Financial Results

    Commercial Channel revenue up 22% with continued strong Integrity™ Implant System and Hyalofast® growth, and double-digit International OA Pain Management growth Third and final Hyalofast PMA module filed and data released Cingal® achieved commercial milestone of more than one million injections worldwide since 2016 Reaffirming Fiscal 2025 guidance and long-term outlook and commencing a $15 million 10b5-1 share repurchase BEDFORD, Mass., Nov. 05, 2025 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ:ANIK), a global leader in the osteoarthritis ("OA") pain management and regenerative solutions spaces focused on early intervention orthopedics, today announced financial results for th

    11/5/25 7:05:00 AM ET
    $ANIK
    Medical/Dental Instruments
    Health Care

    Anika Therapeutics Reports Filing of Final PMA Module for Hyalofast® Cartilage Repair Scaffold and Data from U.S. Pivotal FastTRACK Phase III Study

    BEDFORD, Mass., Nov. 05, 2025 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ:ANIK), a global leader in joint preservation and regenerative solutions, announced that it filed the third and final module of its Premarket Approval application (PMA) for Hyalofast—its resorbable, hyaluronic acid-based scaffold used with autologous bone marrow aspirate concentrate (BMAC) for treating articular cartilage defects in the knee. The Company also reported results from its U.S. pivotal Phase III FastTRACK clinical trial evaluating Hyalofast. On October 31, 2025, Anika submitted the third and final module of its Hyalofast PMA to the U.S. Food and Drug Administration (FDA). The PMA includes FastTRA

    11/5/25 7:00:00 AM ET
    $ANIK
    Medical/Dental Instruments
    Health Care

    Anika to Issue Third Quarter 2025 Financial Results on Wednesday, November 5, 2025

    BEDFORD, Mass., Oct. 23, 2025 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ:ANIK), a global joint preservation company in early intervention orthopedics, announced today that it will issue its third quarter 2025 financial results before the opening of the market on Wednesday, November 5, 2025, followed by a conference call at 8:30 a.m. ET to discuss its results and business highlights. The conference call can be accessed by dialing 1-800-717-1738 (toll-free domestic) or 1-646-307-1865 (international) and providing the conference ID number 53754. A live audio webcast and accompanying presentation materials will be available in the Investor Relations section of Anika's website, www.a

    10/23/25 4:01:16 PM ET
    $ANIK
    Medical/Dental Instruments
    Health Care

    Director Vogt Susan L N was granted 14,164 shares, increasing direct ownership by 39% to 50,213 units (SEC Form 4)

    4 - Anika Therapeutics, Inc. (0000898437) (Issuer)

    6/24/25 5:14:37 PM ET
    $ANIK
    Medical/Dental Instruments
    Health Care

    Director Richard Stephen was granted 14,164 shares, increasing direct ownership by 42% to 47,871 units (SEC Form 4)

    4 - Anika Therapeutics, Inc. (0000898437) (Issuer)

    6/24/25 5:13:40 PM ET
    $ANIK
    Medical/Dental Instruments
    Health Care

    Director Larsen Glenn R. was granted 14,164 shares, increasing direct ownership by 39% to 50,258 units (SEC Form 4)

    4 - Anika Therapeutics, Inc. (0000898437) (Issuer)

    6/24/25 5:13:04 PM ET
    $ANIK
    Medical/Dental Instruments
    Health Care

    $ANIK
    Financials

    Live finance-specific insights

    View All

    Anika Reports Third Quarter 2025 Financial Results

    Commercial Channel revenue up 22% with continued strong Integrity™ Implant System and Hyalofast® growth, and double-digit International OA Pain Management growth Third and final Hyalofast PMA module filed and data released Cingal® achieved commercial milestone of more than one million injections worldwide since 2016 Reaffirming Fiscal 2025 guidance and long-term outlook and commencing a $15 million 10b5-1 share repurchase BEDFORD, Mass., Nov. 05, 2025 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ:ANIK), a global leader in the osteoarthritis ("OA") pain management and regenerative solutions spaces focused on early intervention orthopedics, today announced financial results for th

    11/5/25 7:05:00 AM ET
    $ANIK
    Medical/Dental Instruments
    Health Care

    Anika to Issue Third Quarter 2025 Financial Results on Wednesday, November 5, 2025

    BEDFORD, Mass., Oct. 23, 2025 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ:ANIK), a global joint preservation company in early intervention orthopedics, announced today that it will issue its third quarter 2025 financial results before the opening of the market on Wednesday, November 5, 2025, followed by a conference call at 8:30 a.m. ET to discuss its results and business highlights. The conference call can be accessed by dialing 1-800-717-1738 (toll-free domestic) or 1-646-307-1865 (international) and providing the conference ID number 53754. A live audio webcast and accompanying presentation materials will be available in the Investor Relations section of Anika's website, www.a

    10/23/25 4:01:16 PM ET
    $ANIK
    Medical/Dental Instruments
    Health Care

    Anika Reports Second Quarter 2025 Financial Results

    Regenerative Solutions revenue up 41% with Integrity™ Implant System ahead of expectations and continued strong Hyalofast® growth; Integrity surpasses full year 2024 performance and is on pace to more than double in 2025 Company released topline results for Hyalofast® clinical trial which did not meet pre-specified co-primary end points; Hyalofast demonstrated statistically significant improvements in pre-defined secondary endpoints and other measures; Company plans to file the final PMA module in second half 2025 Reaffirming Fiscal 2025 Revenue and EBITDA guidance; revising long-term outlook to reflect potential timing of FDA review for Hyalofast launch BEDFORD, Mass., July

    7/30/25 7:05:25 AM ET
    $ANIK
    Medical/Dental Instruments
    Health Care

    $ANIK
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Anika Therapeutics Inc.

    SC 13G/A - Anika Therapeutics, Inc. (0000898437) (Subject)

    11/8/24 2:17:24 PM ET
    $ANIK
    Medical/Dental Instruments
    Health Care

    SEC Form SC 13D/A filed by Anika Therapeutics Inc. (Amendment)

    SC 13D/A - Anika Therapeutics, Inc. (0000898437) (Subject)

    5/30/24 4:31:25 PM ET
    $ANIK
    Medical/Dental Instruments
    Health Care

    SEC Form SC 13D/A filed by Anika Therapeutics Inc. (Amendment)

    SC 13D/A - Anika Therapeutics, Inc. (0000898437) (Subject)

    3/6/24 7:30:09 PM ET
    $ANIK
    Medical/Dental Instruments
    Health Care

    $ANIK
    Leadership Updates

    Live Leadership Updates

    View All

    Politan Details Why a Truly Independent Board is Urgently Needed at Masimo in Order to Protect Shareholder Value and Realize the Company's Full Potential

    Sends Letter to Masimo Shareholders and Releases 160-Page Investor Presentation Urges Shareholders to Help Deliver Immediate Change by Voting for Both of Politan's Independent and Ideally Qualified Nominees Darlene Solomon and William Jellison on the WHITE Card Shareholders Can Visit www.AdvanceMasimo.com for Further Information Politan Capital Management (together with its affiliates, "Politan"), an 8.9% shareholder of Masimo Corporation ("Masimo" or the "Company") (NASDAQ:MASI), today sent a letter to the Company's shareholders outlining why a majority of truly independent directors are urgently needed in the Masimo boardroom. Politan also released a detailed investor presentation m

    6/26/24 8:00:00 AM ET
    $A
    $ANIK
    $AVNT
    Biotechnology: Laboratory Analytical Instruments
    Industrials
    Medical/Dental Instruments
    Health Care

    Anika Enters into Cooperation Agreement with Caligan Partners

    Appoints Joseph Capper and William Jellison to Board of DirectorsAnnounces New $40 Million Share Repurchase Program BEDFORD, Mass., May 28, 2024 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ:ANIK), a global joint preservation company in early intervention orthopedics, today announced that it has entered into a cooperation agreement with Caligan Partners LP ("Caligan"). As part of the agreement, Joseph Capper, CEO of MIMEDX, and William Jellison, former CFO of Stryker, have been appointed to the Company's Board of Directors, effective immediately. Messrs. Capper and Jellison have nearly 50 years of combined experience building value and driving transformative growth at MedTech compa

    5/28/24 4:05:00 PM ET
    $ANIK
    Medical/Dental Instruments
    Health Care

    Anika Announces CFO Transition

    BEDFORD, Mass., May 08, 2024 (GLOBE NEWSWIRE) -- Anika Therapeutics, Inc. (NASDAQ:ANIK), a global joint preservation company in early intervention orthopedics, today announced that it has appointed Steve Griffin as the Company's Executive Vice President, Chief Financial Officer ("CFO") and Treasurer, effective June 3, 2024. He succeeds Michael Levitz, who has decided to step down as CFO after almost four years with the company. Mr. Levitz will remain with the Company through December 31, 2024, to ensure a smooth transition. "We are pleased to welcome Steve to Anika as we focus on accelerating our pivot to profitability," said Cheryl Blanchard, Ph.D., Anika's President and CEO. "Steve

    5/8/24 4:08:54 PM ET
    $ANIK
    $VSEC
    Medical/Dental Instruments
    Health Care
    Military/Government/Technical
    Consumer Discretionary